image
Conservation

Compilation of herbal plants (description, geographical distribution, taxonomy, line drawings), biodiversity and herbarium.

Read More
image
Research & Publication

Description of herbal and T&CM research, searchable publication and process from medicinal plant discovery to clinical trial in producing a high-quality registered herbal drug.

Read More
 
Traditional & Complementary Medicine (T&CM)

 

Definition and description of therapies, policy, training and education, research in the practise of (T&CM) and integrated medicine system.           

Read More

 

News Update

Announcement & Advertisement

Forthcoming Events

International Conference on Biotechnology and Healthcare

From Mon, 7. December 2020 Until Tue, 8. December 2020

International Conference on Malay Medical Manuscript

From Tue, 15. December 2020 Until Wed, 16. December 2020

International Conference on Natural Medicine and Nutrition (ICNMN) 2020

From Thu, 17. December 2020 Until Fri, 18. December 2020

1st Global Summit on Generic Drugs and Quality Control

From Fri, 22. January 2021 Until Sat, 23. January 2021

International Conference on Natural Products and Drug Discovery (ICNPDD) 2021

From Thu, 11. February 2021 Until Fri, 12. February 2021

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group

Author

Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al

Date

25/12/1996

Journal

JAMA

Abstract

OBJECTIVE: To determine whether a nutritional supplement of selenium will decrease the incidence of cancer. DESIGN: A multicenter, double-blind, randomized, placebo-controlled cancer prevention trial. SETTING: Seven dermatology clinics in the eastern United States. PATIENTS: A total of 1312 patients (mean age, 63 years; range, 18-80 years) with a history of basal cell or squamous cell carcinomas of the skin were randomized from 1983 through 1991. Patients were treated for a mean (SD) of 4.5 (2.8) years and had a total follow-up of 6.4 (2.0) years. INTERVENTIONS: Oral administration of 200 microg of selenium per day or placebo. MAIN OUTCOME MEASURES: The primary end points for the trial were the incidences of basal and squamous cell carcinomas of the skin. The secondary end points, established in 1990, were all-cause mortality and total cancer mortality, total cancer incidence, and the incidences of lung, prostate, and colorectal cancers. RESULTS: After a total follow-up of 8271 person-years, selenium treatment did not significantly affect the incidence of basal cell or squamous cell skin cancer. There were 377 new cases of basal cell skin cancer among patients in the selenium group and 350 cases among the control group (relative risk [RR], 1.10; 95% confidence interval [CI], 0.95-1.28), and 218 new squamous cell skin cancers in the selenium group and 190 cases among the controls (RR, 1.14; 95% CI, 0.93-1.39). Analysis of secondary end points revealed that, compared with controls, patients treated with selenium had a nonsignificant reduction in all-cause mortality (108 deaths in the selenium group and 129 deaths in the control group [RR; 0.83; 95% CI, 0.63-1.08]) and significant reductions in total cancer mortality (29 deaths in the selenium treatment group and 57 deaths in controls [RR, 0.50; 95% CI, 0.31-0.80]), total cancer incidence (77 cancers in the selenium group and 119 in controls [RR, 0.63; 95% CI, 0.47-0.85]), and incidences of lung, colorectal, and prostate cancers. Primarily because of the apparent reductions in total cancer mortality and total cancer incidence in the selenium group, the blinded phase of the trial was stopped early. No cases of selenium toxicity occurred. CONCLUSIONS: Selenium treatment did not protect against development of basal or squamous cell carcinomas of the skin. However, results from secondary end-point analyses support the hypothesis that supplemental selenium may reduce the incidence of, and mortality from, carcinomas of several sites. These effects of selenium require confirmation in an independent trial of appropriate design before new public health recommendations regarding selenium supplementation can be made.

Explore Further

Consumer Data

Consumer data including medicinal herbs, dietary supplement monographs, health condition monographs and interactions and depletions.                                    

Read More
Professional Data

Professional data organized into medicinal herbs, dietary supplement monographs, health condition monographs, T&CM herbs, formulas, health conditions, interactions and depletions.

Read More
International Data

We offer International linkages to provide extensive content pertaining to many facets of T&CM as well as Integrated Medicine. Please register for access.    

Read More